Citius Pharmaceuticals Inc (CTXR)
0.1269
-0.04
(-23.14%)
USD |
NASDAQ |
Nov 22, 14:30
Citius Pharmaceuticals Enterprise Value: 12.53M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 12.53M |
| November 20, 2024 | 13.39M |
| November 19, 2024 | 17.35M |
| November 18, 2024 | 23.21M |
| November 15, 2024 | 18.83M |
| November 14, 2024 | 42.04M |
| November 13, 2024 | 52.40M |
| November 12, 2024 | 69.84M |
| November 11, 2024 | 63.87M |
| November 08, 2024 | 57.06M |
| November 07, 2024 | 51.76M |
| November 06, 2024 | 45.40M |
| November 05, 2024 | 45.89M |
| November 04, 2024 | 45.76M |
| November 01, 2024 | 47.55M |
| October 31, 2024 | 50.05M |
| October 30, 2024 | 55.83M |
| October 29, 2024 | 53.24M |
| October 28, 2024 | 49.54M |
| October 25, 2024 | 48.47M |
| October 24, 2024 | 45.22M |
| October 23, 2024 | 47.23M |
| October 22, 2024 | 49.38M |
| October 21, 2024 | 52.12M |
| October 18, 2024 | 53.35M |
| Date | Value |
|---|---|
| October 17, 2024 | 56.79M |
| October 16, 2024 | 57.15M |
| October 15, 2024 | 50.30M |
| October 14, 2024 | 46.94M |
| October 11, 2024 | 49.05M |
| October 10, 2024 | 55.00M |
| October 09, 2024 | 53.57M |
| October 08, 2024 | 52.88M |
| October 07, 2024 | 54.08M |
| October 04, 2024 | 61.12M |
| October 03, 2024 | 63.22M |
| October 02, 2024 | 67.54M |
| October 01, 2024 | 67.29M |
| September 30, 2024 | 73.16M |
| September 27, 2024 | 77.01M |
| September 26, 2024 | 76.12M |
| September 25, 2024 | 76.00M |
| September 24, 2024 | 80.28M |
| September 23, 2024 | 82.25M |
| September 20, 2024 | 85.68M |
| September 19, 2024 | 81.74M |
| September 18, 2024 | 74.86M |
| September 17, 2024 | 73.23M |
| September 16, 2024 | 73.92M |
| September 13, 2024 | 76.65M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.43M
Minimum
Dec 04 2019
470.30M
Maximum
Jun 21 2021
113.56M
Average
105.97M
Median
Enterprise Value Benchmarks
| Citius Oncology Inc | -- |
| Agilent Technologies Inc | 39.10B |
| Merck & Co Inc | 276.21B |
| Cara Therapeutics Inc | -25.03M |
| Moleculin Biotech Inc | -0.9096M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.57M |
| Total Expenses (Quarterly) | 10.63M |
| EPS Diluted (Quarterly) | -0.06 |
| Earnings Yield | -189.1% |